«After 50 years establishing itself as one of the largest pharma companies in China, Jiangsu Hengrui Pharmaceuticals is launching Luzsana Biotechnology targeted at the global market. With a unique operating model, the Hengrui subsidiary aims to “quantifiably reduce costs” of medicines, its CEO said.»
«Originally Hengrui’s U.S. and European operations, Luzsana officially hangs its plaque Wednesday with a pipeline of 11 drugs from the parent led by China-approved PD-1 cancer immunotherapy camrelizumab.»
«Luzsana has its name rooted in “la luz,” which is Spanish for light, and “sana,” which is Latin for heal. The name therefore reflects the company’s aspiration to become a “healing light.”»
Article written by Angus Liu.